Is chronic lymphocytic leukemia one disease?

Haematologica

Volumn 87, Issue 12, 2002, Pages 1233-1235

  Dighiero, Guillaume ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; IMMUNOGLOBULIN;

ADULT; CANCER CHEMOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG INDICATION; GENE EXPRESSION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; ONSET AGE; PHENOTYPE; PROGNOSIS; SPLENOMEGALY; SURVIVAL TIME; TREATMENT INDICATION;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENES, IMMUNOGLOBULIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM STAGING; PROGNOSIS;

EID: 0036902992     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: Analysis of the antibody repertoire. Immunol Today 1994; 15:288-94.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-34.
3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198-206.
4. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338:1506-14.
5. Anonymous. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999; 91:861-8.
6. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S. The serum ß2-microglobulin (ß2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 1998; 86:606a [abstract #2412].
7. Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988; 71:94-8.
8. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Ador D, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93:1732-7.
9. Dohner H, Stilgebauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-6.
10. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7.
11. Hamblin TJ, Davis Z, Oscier DG, Stevenson FK. Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-55.
12. Maloum K, Pritsch O, Magnac C, Vuillier F, Davi F, Troussard X, Mauro FF, et al. Expression of unmutated VH genes is a detrimental prognostic factor in Chronic Lymphocytic Leukemia. Blood 2000; 96:377-9.
13. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous pheno-type related to memory B cells. J Exp Med 2001; 194: 1625-38.
14. Rosenwald A, Alizadeh AA, Widhopf G Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639-47.